Category: Article

Up the Stack: Why the Real Frontier of AI Lives Between Your Laboratory Instruments

A single high-resolution instrument run can generate several gigabytes of data in minutes. That sounds like progress, and it is, until that data sits isolated in a proprietary format that nothing else in the lab can read without manual intervention. This is the quiet ceiling that modern laboratories are hitting: the first wave of “smart” instrument features, automated peak integration, predictive maintenance alerts, solved real problems inside individual instruments, but they never solved the problem between them.

For lab directors, IT architects, and operations managers, this matters because the next phase of laboratory digital transformation isn’t about smarter instruments. It’s about whether the software stack above those instruments can finally talk to all of them at once.

Why do “smart” lab features stop solving problems at the instrument level?

Automated peak integration and predictive maintenance alerts were a genuine step forward; they reduced manual review and caught failures before they became downtime. But Chemetrix’s consultants have seen the same pattern repeat across regional labs: once those features are deployed, the bottleneck doesn’t disappear. It moves. The constraint shifts from “is this instrument performing well” to “can this instrument’s data talk to the next system in the workflow.”

A chromatography system might integrate its own peaks flawlessly and still hand off a result that a LIMS, an ELN, or a second instrument can’t parse without a manual export-and-reformat step. The smart feature did its job. The workflow around it didn’t get any smarter.

Why does fragmented lab data matter beyond the bench?

The instruments driving modern science, high-resolution mass spectrometers, multi-detector chromatography systems, generate data at a scale that simply didn’t exist a decade ago. A single run can produce several gigabytes of fragmented output, structured around a specific vendor’s proprietary format rather than the workflow the data is meant to serve.

This isn’t just an IT inconvenience. Every manual reformatting step is a point where data can be transcribed incorrectly, where context gets lost, and where audit trails become harder to defend. In regulated GxP environments, this kind of fragmentation isn’t a productivity issue, it’s a compliance exposure waiting to surface during an audit.

How does declarative orchestration differ from standard lab integration?

Most current lab integration is imperative: an IT team manually maps Instrument A’s output format to Instrument B’s expected input, instrument by instrument, vendor by vendor. It works, but it’s rigid. Every new instrument, every software update, every vendor change requires re-mapping the connection by hand.

Declarative orchestration works differently. An analyst sets a scientific goal, “run this sample through this workflow”, and the software layer coordinates the instrument fleet to execute it, regardless of which vendor built which piece of hardware. This shift is only possible when the data underneath is described using open, vendor-neutral standards rather than proprietary formats that lock data inside a single system.

This is where frameworks from the Allotrope Foundation, the Pistoia Alliance, and SiLA become directly relevant. The Allotrope Foundation promotes industry standards that enhance data interoperability, aligning laboratory data practices with FAIR and ALCOA+ principles to support data integrity and compliance. SiLA promotes AnIML, a basic-level data format that counters the problem of lab instruments speaking different languages, aiming to align communication between manufacturers using a shared XML-based data format. Together, these standards are what let agentic AI move from a chatbot overlay sitting on top of a single system to genuine cross-instrument orchestration

Closing the data gap for pharmaceutical and GxP labs

For regulated pharmaceutical environments, the stakes around data fragmentation are highest. A multi-step QC workflow that spans HPLC, mass spectrometry, and a LIMS needs every handoff to be defensible during an audit, not just functional day to day.

The Pistoia Alliance’s MethodDB project, developed in collaboration with the Allotrope Foundation and partners including Agilent, Merck, and Bristol-Myers Squibb, uses the Allotrope Data Format to standardise how analytical method descriptions are recorded, increasing data integrity and scientific reproducibility. This kind of standardisation is precisely what reduces the change-management burden GxP labs face when adopting any new automation layer, the data structure underneath stays consistent even as the tools on top evolve.

Chemetrix application specialists work directly with regulated labs across the region to assess where data handoffs currently rely on manual reformatting, and to map a practical path toward standards-based interoperability without disrupting validated workflows already in place.

 

Improving cross-site asset utilisation for multi-lab operations

For organisations running multiple lab sites, instrument-level smart features solve a single-site problem while leaving a bigger one untouched: knowing which instruments across the network are actually available, and routing samples to them efficiently.

This is the orchestration layer gap that the broader industry has started naming directly. Coordination “still happens in calendars and email threads” in many R&D organisations, even where individual instruments are highly automated. Declarative orchestration, built on open data standards, is what allows a scheduling system to see instrument availability across sites and route work accordingly, rather than relying on a person manually checking which lab has capacity.

For multi-site operations evaluating this shift, Chemetrix can walk through a practical asset-utilisation audit, identifying where standards-based data exchange would unlock cross-site scheduling that today depends on manual coordination.

Should labs treat agentic AI as a cure-all for workflow problems?

No, and treating it that way is precisely the steep change-management trap that catches labs out. Agentic AI is only as effective as the data structure underneath it.

Agentic AI systems capable of autonomous planning, tool use, and multi-step reasoning represent a genuinely transformative shift, but the implications come with real governance challenges: how decisions are validated, how audit trails are maintained, and what infrastructure is needed to deploy agents safely at scale. A chatbot layered on top of fragmented, vendor-locked data doesn’t solve the underlying problem, it just adds a conversational interface to the same broken handoffs.

This is the cultural shift Chemetrix advocates for: building the data foundation first, with open standards and genuine interoperability, rather than reaching for an AI overlay as a shortcut around the harder infrastructure work. Labs that get this sequence right end up with systems that are auditable, defensible, and genuinely faster. Labs that skip ahead end up with an impressive demo and the same fragmented data problem underneath.

What should lab directors and IT architects do next?

The shift from instrument-centric benches to integrated, workflow-first ecosystems isn’t optional for labs that want to capture real efficiency gains, but it does require sequencing the work correctly: assess where data handoffs are currently manual, prioritise standards-based interoperability over point-solution AI overlays, and treat regulated change-management requirements as part of the plan from the outset, not an afterthought.

For Lab Directors: Save this guide and start mapping where your current workflow relies on manual data reformatting between instruments.
For IT Architects: Talk to a Chemetrix specialist about evaluating your lab’s readiness for open-standards-based data exchange.
For Operations Managers: Request an asset-utilisation audit to identify where declarative orchestration could improve cross-site scheduling and turnaround time.

TL;DR

First-generation “smart” lab features, automated peak integration, predictive maintenance alerts, solve problems inside a single instrument, but they don’t solve the data gaps between instruments. The real bottleneck is fragmented, vendor-locked data. Open standards like Allotrope, SiLA and the Pistoia Alliance’s frameworks are what let labs move from imperative integration (manual, rigid data mapping) to declarative orchestration, where an analyst sets a scientific goal and software coordinates the fleet, improving turnaround, compliance,
and asset utilisation.

From Weighing to Waste: Streamlining High-Stakes Food and Cannabis Testing with All-in-One Automation

Out-of-spec batches rarely start with a hardware failure. They start at the bench, in the five minutes before a sample ever reaches an instrument. Manual QuEChERS vortexing and multi-step solid-phase extraction are foundational to cannabis and food pesticide testing, but they’re also where the most preventable variance enters a lab’s data.

This matters because the instrument gets the credit when results are accurate, and the blame when they’re not, even when the actual point of failure was a sample prep step that two different analysts performed two different ways. For labs under regulatory turnaround pressure, understanding exactly where that variance originates is the first step to removing it.

Where does analyst variance actually enter the sample prep workflow?

Chemetrix consultants see the same pattern across regional food safety and cannabis testing labs: the analytical instrument is rigorously validated, but the sample preparation feeding it is governed by habit, not protocol. Manual QuEChERS extraction depends on shaking intensity and duration that vary from person to person and shift to shift. Centrifugation speed and timing, layer separation technique, and even how long a sample sits before processing all introduce small inconsistencies that compound across a batch.

None of this shows up as an obvious error. It shows up as drifting recovery rates, inconsistent RSDs, and a lab manager trying to explain why the same method produced different results on different days, with no clear root cause to point to.

 

What’s actually happening to the sample matrix during extraction and cleanup?

Cannabis and complex food matrices are chemically demanding to work with. Pigments like chlorophyll and carotenoids, along with waxes and other co-extractives, need to be removed during cleanup without stripping out the target pesticides alongside them. This is a genuinely difficult balance, and it’s why the physical variables in manual prep matter so much: pipetting accuracy affects how much sorbent or solvent reaches the sample, evaporation rate affects how concentrated or degraded an extract becomes, and centrifugal consistency determines whether phase separation is clean or compromised.

When these variables shift slightly between analysts, the chemistry shifts with them, sometimes enough to push a result above or below a regulatory threshold for reasons that have nothing to do with the actual sample.

How does standardising sample prep actually improve lab efficiency?

The efficiency gain from automating sample prep isn’t just about saving hands-on time, though that matters too. It’s about removing the variable entirely so that every sample, regardless of which analyst loaded it or which day it ran, goes through an identical physical and chemical process. Chemetrix’s work designing complete sample prep solutions across regional labs consistently shows that standardisation, not faster individual steps, is what actually closes the gap between a method that works in validation and one that holds up in routine high-throughput use.

This is also where sourcing matters. A lab juggling QuEChERS salts, SPE cartridges, and pesticide reference standards from multiple suppliers loses time before testing even starts, reconciling part numbers, managing inventory gaps, and troubleshooting inconsistent batches of consumables that were never designed to work together as a system.

Automating QuEChERS extraction for pesticide residue Testing

For labs running high-volume pesticide residue testing in food and cannabis matrices, the Raykol Automated DRQ QuEChERS system addresses analyst variance directly by automating the entire extraction sequence, solvent addition, salt addition, vortexing, centrifugation, and layer separation, in a single workstation. Only sample weighing remains manual, which means every other physical variable that previously depended on individual technique is now executed identically, run after run.

The system supports up to 60 samples per batch and 120 samples per day, with fully programmable workflows that can be adjusted for pesticides, veterinary drugs, or herbal matrices depending on the lab’s testing scope. For labs evaluating this transition, Chemetrix offers complete, pre-verified consumable kits covering QuEChERS extraction salts, SPE cleanup products, and certified pesticide reference standards, all matched to the DRQ workflow on a single ordering guide, removing the multi-vendor sourcing overhead entirely.

Eliminating cleanup variance through integrated SPE and evaporation

Solid-phase extraction cleanup is typically a multi-step manual process, loading cartridges, controlling flow rate, evaporating eluent, and reconstituting the sample, each step introducing its own opportunity for inconsistency. An integrated SPE and evaporation system performs purification, concentration, solvent exchange, and reconstitution within a single automated platform, removing the manual handoffs between steps that are most prone to analyst-to-analyst drift.

This kind of integration is particularly valuable for labs handling viscous or matrix-heavy samples, where manual evaporation timing is one of the hardest variables to keep consistent. Chemetrix application specialists work directly with regional labs to map current SPE workflows against automated configurations, and can also walk teams through a related webinar on cannabis and food matrix cleanup strategy for labs evaluating the transition.

Should labs accept analyst variance as a normal cost of manual testing?

No. There’s a quiet assumption in a lot of labs that some degree of analyst-to-analyst variance is simply the price of running a busy testing operation. It isn’t. It’s a solvable workflow design problem, not an inevitable feature of working with people instead of robots.

Chemetrix’s role isn’t to suggest that automation replaces skilled analysts, it’s to free those analysts from manually executing repetitive physical steps that machines perform more consistently, so their expertise goes toward method development, troubleshooting and the judgment calls that actually require a trained scientist. That’s the standard Chemetrix holds its sample prep solutions to: protecting the lab’s long-term data integrity, not just its short-term throughput numbers.

What should your lab do next to standardise sample prep?

Out-of-spec batches and inconsistent recovery rates are rarely an instrument problem. More often, they trace back to manual sample preparation steps that vary between analysts in ways that are easy to overlook and difficult to diagnose after the fact. Automating QuEChERS extraction and SPE cleanup removes that variance at the source, while complete consumable kits eliminate the sourcing friction that slows labs down before testing even begins.

For Lab Managers: Save this guide and review where your current sample prep workflow relies on individual analyst technique rather than a standardised protocol.
For Evaluating Specialists: Request application guidance on matching the Raykol DRQ or integrated SPE-evaporation system to your specific matrix and throughput requirements.
For Compliance Custodians: Talk to a Chemetrix specialist about documenting standardised sample prep protocols as part of your audit-ready quality controls.

TL;DR

Manual QuEChERS extraction and multi-step SPE cleanup introduce measurable analyst-to-analyst variance, in shaking intensity, centrifugal consistency, and evaporation timing, that drives inconsistent pesticide recovery and out-of-spec batches. Automated platforms like the Raykol DRQ QuEChERS system and integrated SPE-evaporation workstations remove that variance entirely, while complete, pre-verified consumable kits eliminate the sourcing overhead that slows labs down before testing even begins.

The Crippled Treatment Works

A municipal district in Gauteng plunges into a public health emergency. Dozens of lives lost, hundreds hospitalised, local food producers forced to halt production over unpotable water, and a municipality facing serious legal and compliance liability over a failing utility grid.

This isn’t a hypothetical. It’s the pattern behind real waterborne disease outbreaks linked to wastewater infrastructure failure and at the centre of it is a testing gap that’s entirely preventable.

By the time legacy laboratory methods confirm contamination, the public has often already consumed the water. This matters for every lab and utility responsible for drinking water safety, because the difference between catching contamination in hours versus days is the difference between an isolated incident and a catastrophe.

What happens when a wastewater treatment plant fails?

An over-capacitated, poorly maintained wastewater treatment plant operating far above its design limits doesn’t just underperform, it actively becomes the source of the crisis. Instead of discharging treated, compliant effluent, the dysfunctional plant releases millions of litres of partially treated sewage directly into the river system feeding a downstream drinking water purification plant.

This is rarely a sudden failure. It’s the result of ageing infrastructure, deferred maintenance, and a system running past its intended capacity for years before the consequences become visible at the tap.

 

How does E. coli contamination escalate from “manageable” to “catastrophic”?

The daily reality of this kind of failure isn’t measured in headlines, it’s measured in microbiological density. Upstream of a failing wastewater plant, a river might carry a manageable 5,000 CFU of E. coli per 100ml. Downstream of the same plant, that number can rocket to 1,000,000 CFU per 100ml.

This overwhelming biological load depletes dissolved oxygen in the river ecosystem and introduces highly pathogenic strains that overwhelm standard sand filtration and multi-barrier chlorination at the downstream drinking water plant, allowing coliforms to enter the reticulation network and reach the public.

Why is legacy water testing too slow to prevent an outbreak?

Traditional water testing relies on retrospective culture methods, incubating samples and waiting for bacterial growth to confirm contamination. The problem isn’t the accuracy of this method. It’s the timeline. Culture-based testing can take days to deliver results, and during a wastewater infrastructure failure, days is exactly the window in which the public is already drinking contaminated water.

 

By the time a lab confirms the failure, the exposure has already happened.
The diagnostic gap, not a lack of awareness, is what turns a fixable infrastructure problem into a public health emergency.

How does rapid water quality testing close that gap?

The fix isn’t more frequent legacy testing, it’s a fundamentally faster method. High-throughput enzymatic assays and rapid Quantitative PCR (qPCR) screens detect shifting microbial index markers and indicator spikes within hours rather than days, aligned strictly to SANS 241 drinking water standards.

That speed changes what’s possible operationally. Lab managers can use same-day data to alter chemical dosing, isolate affected reservoirs, and flag a wastewater failure before it cascades into a full-scale contamination event, turning a containable infrastructure problem back into exactly that, instead of a human catastrophe.

 

Should municipal and industrial labs rethink their testing protocols?

For utilities, municipal labs, and the commercial industries that depend on potable water supply, food and beverage producers especially, relying solely on legacy culture testing is a defensible-sounding but operationally risky position. “We tested it” isn’t the same as “we tested it fast enough to act.” Rapid, automated profiling aligned to SANS 241 gives labs the diagnostic speed that legacy methods were never built to provide.

FAQ

How fast can rapid water testing detect contamination compared to traditional methods?

Rapid qPCR and enzymatic assays can detect microbial contamination within hours, compared to days for traditional culture-based testing methods.

What is SANS 241?

SANS 241 is South Africa’s national drinking water quality standard, setting the microbiological, chemical, and aesthetic limits water must meet to be considered safe for public consumption.

Why does E. coli concentration matter for water safety?

High E. coli concentrations indicate faecal contamination and the likely presence of other pathogenic bacteria, signalling a direct health risk to anyone exposed to the water.

What should your lab do before the next wastewater failure?

When wastewater infrastructure fails, the difference between a contained incident and a public health catastrophe often comes down to testing speed. Legacy culture methods confirm contamination days too late. Rapid, SANS 241-aligned qPCR and enzymatic screening close that gap to hours — giving lab managers and utilities the window they need to act.

TL;DR

A failing municipal wastewater plant can push E. coli levels from 5,000 to 1,000,000 CFU/100ml downstream, overwhelming drinking water filtration and triggering public health crises. Legacy culture-based testing detects this days after exposure. Rapid qPCR and enzymatic assays, aligned to SANS 241, flag contamination within hours, giving labs the window to act before a wastewater failure becomes a human catastrophe.

Beyond the Quartz Waterline: The True Cost of Chemical Attack in High-TDS ICP–OES Analysis

It’s 4:30pm on a Friday, and your calibration standards have started drifting. Not failing outright, just enough to make you squint at the screen and wonder if it’s the method, the standards, or something else entirely. You’ve run high-TDS samples all week. You already know what you’ll find when you pull the torch: a faint haze of devitrification creeping up the quartz, the first sign that your “reliable” consumable has quietly started lying to you.

This is one of the most common, and most under-discussed, failure points in ICP-OES analysis. Standard quartz torches are excellent components, but they were never built to survive sustained exposure to high total dissolved solids (TDS), complex organic matrices, or heavy alkaline-earth and alkali metal loads (Li, Na, K, Ca, Mg, Rb, Cs). When labs run these matrices routinely, the torch becomes the silent variable behind drifting baselines, unexplained reruns and consumable budgets that never seem to add up.

This matters because most labs are still buying consumables on sticker price, not on cost per sample and that one decision is quietly driving the downtime, rework and accuracy issues everyone blames on “the instrument.”

Why does my ICP-OES torch keep failing on high-matrix samples?

Every analyst who’s run high-matrix samples for any length of time has lived this story. You start the week with a torch that performs beautifully. By Wednesday, you’re seeing slightly elevated background noise. By Friday, the quartz has started to devitrify, that cloudy, crystalline degradation that happens when alkaline-earth salts attack the silica structure under plasma heat. The glass becomes structurally weaker, more porous, and less optically clean, and your results start drifting in ways that don’t show up until you’ve already reported a few batches.

The instinctive response in most labs is to try to revive it: scrub it, soak it, polish it, swap in a “spare” that’s already half-degraded. Chemetrix consultants see this pattern across hundreds of labs in the region, teams spending real hours trying to nurse a structurally compromised torch back to usable condition, when the real fix has nothing to do with cleaning technique and everything to do with material selection. It’s not a bad habit. It’s a consumable mismatched to the matrix.

 

Why does quartz fail but ceramic doesn’t?

It’s easy to think of a torch as just a piece of glassware sitting inside an instrument. But every high-TDS or alkaline-earth-rich sample that runs through a degraded torch is, somewhere downstream, a decision that affects someone outside the lab. A mining company relies on accurate trace metal data to prove environmental compliance. A food producer relies on it to confirm a batch is safe to ship. A water utility relies on it to confirm a community’s tap water meets safety limits. None of those decisions are better than the data behind them, and that data is only as good as the consumable it passed through.

This is the part of analytical chemistry that rarely gets discussed outside the lab: the instrument doesn’t make the result trustworthy, the entire chain does, right down to whether the torch was chemically stable enough to deliver a clean, repeatable plasma. When a torch is quietly devitrifying, the risk isn’t just rework for the analyst, it’s a small crack in the chain of trust between a lab result and the public decision built on top of it.

That’s exactly why Chemetrix exists in this conversation, not to sell glassware, but to make sure the science underneath these decisions is as solid as the stakes riding on it.

Is a cheaper ICP-OES torch actually cheaper?

Quartz wins on the quote. But the real cost shows up later, in reruns, manual cleaning hours, replacement downtime, and accuracy risk from consumables run past their usable life. Compare cost per sample instead of cost per torch, and silicon nitride ceramic outer tubes, lasting up to 10x longer than quartz, win decisively.

How do you streamline a high-matrix ICP-OES workflow?

Most labs set their torch configuration once at installation and never revisit it as sample types change. Chemetrix’s solution design experience points to a simple fix: match outer tube and injector material to the matrix before degradation starts, and use demountable platforms so only the stressed component needs replacing.

Best torch setup for mining and environmental labs

Mining and environmental labs run heavy alkaline-earth, high-TDS matrices that strip standard quartz fastest. The Agilent 5800/5900 Series ICP-OES with demountable torches and silicon nitride ceramic outer tubes lets labs replace only the stressed component. See the 5000 Series Quick Reference Guide or watch the demountable torch video.

Agilent 5900 ICP-OES

Preventing injector damage in food, beverage, and petrochemical testing

Complex organic matrices attack injector material rather than the outer tube, causing drift and blockages. Agilent’s full-range alumina injectors let labs configure a torch matched to organic-heavy samples without sacrificing durability. See the vertical torch technical overview, or talk to a Chemetrix specialist.

 

Should labs just “cope” with outdated systems?

Frequent torch failure isn’t just part of the job, it’s a symptom of consumable choices built around short-term cost. Chemetrix exists to challenge that: helping labs build a culture of integrity, accuracy, and respect for the people doing the work, starting with the right consumable, chosen properly.

What should you do next to protect your ICP-OES accuracy and uptime?

Recurring drift, frequent torch replacement, and hours lost to manual cleaning point to one culprit: the consumable, not the method. Silicon nitride ceramic and full-range alumina injectors offer up to 10x the lifespan of quartz, with less downtime and better accuracy.

TL;DR:

Standard quartz ICP-OES torches degrade quickly under high-TDS, alkaline-earth, or complex organic matrices, driving baseline drift, reruns, and downtime. Agilent’s silicon nitride ceramic outer tubes last up to 10x longer than quartz and full-range alumina injectors resist chemical attack; together lowering true cost per sample and protecting accuracy.

How to Get Reliable FTIR Identification Every Time with the Agilent Cary 630

Your raw material just failed its FTIR identity check. The match score came back at 87%, the batch is on hold and three people are standing around a spectrometer debating whether to reject a container of perfectly good excipient.

Here is the hard truth: in most cases, the material is fine. The instrument is fine. The problem is a misunderstanding of what FTIR matching actually measures, and it is costing pharmaceutical QC labs hours of unnecessary retesting, false rejections and eroded confidence in a technology that is genuinely excellent at its job.

This article unpacks the three real causes of low match scores, what FTIR can and cannot tell you, and how to build a workflow that turns your spectrometer into the trusted identification workhorse it was designed to be.

 

Why does my FTIR keep giving me low match scores?

Walk into most pharmaceutical QC labs and you will see some version of the same frustration. A technician places a powder loosely on the diamond crystal, presses the plunger halfway down, gets a poor match score and logs it as a suspected material failure. After years of working alongside QC teams across hundreds of laboratories, the Chemetrix team can tell you that this scenario almost always comes down to one of three things.

Poor ATR crystal contact: Infrared light only penetrates a few micrometres into the sample surface. Air gaps or inconsistent pressure mean the evanescent wave never reaches the material properly, producing a weak and noisy spectrum that will not match any reference cleanly.

Generic reference libraries: Most labs rely on commercial libraries built from a single reference sample under ideal conditions. When your actual material arrives with slight batch variation, a different particle size or minor additives, it will not match that idealised reference, even if it is exactly the right material.

Misplaced expectations: A match score measures similarity under the conditions of measurement. It is not an absolute verdict on material identity. Even a correct material from the correct supplier can return a score well below 100% if technique or library quality is off.

The good news is that all three of these problems are fixable.

What is FTIR actually measuring?

FTIR spectroscopy works by focussing on infrared light at a sample and measuring which wavelengths the material absorbs. Every compound has a unique pattern of absorption peaks, its molecular fingerprint. The ATR (attenuated total reflectance) method makes this fast and practical by bouncing the infrared beam off a diamond crystal in contact with the sample, requiring no preparation beyond placing the material on the sensor.

Library matching then compares your sample’s fingerprint to a reference spectrum using a mathematical correlation algorithm. The result is a match score, not a binary yes or no,
but a measure of how similar the two spectra are under the conditions of that measurement. Importantly, standard library search methods are designed to detect differences in the 5 to 10% range between a sample and its reference, which means some variation is expected
and entirely normal.

This is a critical distinction. Natural spectral variation occurs between batches of the same material due to:

  • Moisture content and surface effects
  • Particle size differences between suppliers or manufacturing runs
  • Trace additives or stabilisers that are entirely acceptable within specification

None of these make the material wrong. But all of them will affect your match score if your reference library was not built to account for them.

Here is the insight that changes everything:

FTIR is an identification tool, not a purity tool. It will tell you what something is. It will not tell you how pure it is or quantify trace impurities. That is the job of HPLC. Stop asking your FTIR to do HPLC’s work and start letting it be the world-class ID workhorse it was built to be.

How do you improve ATR sample preparation?

Consistent results require consistent technique.
These are the four rules that make the biggest difference:

Powders: Spread the sample evenly across the full crystal surface before pressing. Apply firm and consistent downward pressure using the sample press. If the signal is weak, press harder and recollect the background.

Hard solids: Press a flat face directly onto the crystal or grind a small portion to a fine powder first. A smooth surface fragment beats a large irregular chunk every time.

Pastes and semi-solids: Apply a thin even layer onto the ATR surface with a spatula. These conform naturally to the crystal and are the easiest sample type to handle well.

Crystal hygiene: Clean the crystal between every sample with an appropriate solvent and a lint-free cloth. A contaminated crystal from the previous sample is an invisible source of error that will affect match scores across multiple runs.

Standardising these steps into a written SOP, what Chemetrix calls the “SOP of the Squeeze”, is the single fastest way to improve reproducibility across your team.

How can you build a pharmaceutical FTIR library that actually works?

The solution to false rejections in pharmaceutical raw material identification is not to lower your acceptance thresholds. It is to build a smarter library. A site-specific library collects reference spectra from your own approved batches of each material, across multiple suppliers and multiple delivery lots, so that the natural variation of your actual materials is built into the reference from the start. When a new batch arrives with slightly different moisture content or particle size, your library recognises it as the correct material because it has seen that variation before.

The instrument that makes this possible: the Agilent Cary 630 FTIR

The Cary 630 is purpose-built for pharmaceutical QC applications. Its instrument configuration delivers energy throughput up to 30% greater than comparable routine FTIR systems, which means faster data collection, lower noise and more reliable spectra even when sample variation is present. Its diamond ATR crystal is impervious to abrasion, requires very small amounts of sample and is easy to clean between samples. Modular sampling accessories click in and out in seconds with no alignment required, and at just 20 x 20 cm on the bench and 3.8 kg, it lives where the work happens rather than in a centralised lab.

 

 

Most importantly, the Cary 630 runs Agilent MicroLab software, a method-driven and pictorial interface that makes building site-specific libraries an intuitive task rather than a data science project. MicroLab supports advanced classification methods including PLS-DA (partial least squares discriminant analysis). In published testing using the Cary 630 with MicroLab, a PLS-DA method achieved 100% correct classification of pharmaceutical samples and detected contaminants at levels as low as 0.5%. Results are displayed as colour-coded pass/fail indicators and automatically logged in 21 CFR Part 11 compliant audit trails.

This is what Chemetrix calls the Golden Reference Library: a site-specific and validated collection of spectra that reflects your materials, your suppliers and your real-world conditions. Not a generic database. Yours.

 

Practical resources:

What does a validated FTIR library mean for regulatory compliance?

For pharmaceutical manufacturers operating in a regulated environment, a site-specific library is not just a practical improvement. It is a compliance asset. The Cary 630 meets or exceeds the performance specifications of the US, European, Japanese, Chinese, Indian and International Pharmacopoeia. Its automated IQ/OQ qualification software generates documented and auditable performance reports covering wavenumber accuracy, spectral resolution and signal-to-noise ratio. MicroLab OQ handles qualification for the US, European and Indian Pharmacopoeia directly, while MicroLab PC can be configured for additional requirements including the Japanese Pharmacopoeia. The optional MicroLab Pharma software package adds full 21 CFR Part 11 and EU Annex 11 support including electronic signatures and data integrity controls.

 

But instrument qualification is only one part of the compliance picture. A validated reference library, with documented collection conditions, approved batch traceability and defined acceptance criteria, is what gives your QA team the scientific and regulatory confidence to act on FTIR results without
second-guessing every match score.

Chemetrix supports clients through the full validation process, from initial library design through to IQ/OQ documentation and method verification against pharmacopoeial requirements.

Practical resources:

📌 Contact Chemetrix to discuss validation support for your FTIR workflow.

There is a better way to run your QC lab

Too many pharmaceutical QC labs have quietly accepted that FTIR is unreliable. They have added extra retesting steps. They have lowered thresholds without understanding why. They have learned to work around the instrument rather than with it. That is not good science. And it is not a sustainable way to run a quality control operation. Chemetrix believes that every lab, regardless of its size, its budget or its current frustrations, deserves instrumentation that works, workflows that are documented and a team that understands what their results actually mean.

The Cary 630 is not just sold and installed. Chemetrix partners with your team through three practical engagement points:

  • Workflow audit: Identifying exactly why your current match scores are low and where the process is breaking down
  • Method development Assistance: Building and documenting the SOP of the Squeeze that standardises ATR technique across your team
  • Validation support: Ensuring your custom library meets the compliance requirements of your QC environment

When your library is right and your technique is standardised, FTIR stops being a source of anxiety. It becomes what it was always supposed to be: fast, reliable and auditable identification, every time.

 

Low FTIR match scores are almost never an instrument problem.
They are a library problem or a technique problem, and both are fixable.

The three things to take away from this article:

    • A match score measures similarity under the conditions of measurement. Natural batch variation, particle size differences and trace additives will affect it even when the
      material is correct.
    • ATR sample preparation technique has a bigger impact on match scores than most labs realise. Standardising your approach with a documented SOP is the fastest win available.
    • A site-specific library built from your own approved batches will outperform any generic commercial database for your materials, in your lab and from your suppliers.

The Agilent Cary 630 FTIR makes the instrument side of this straightforward. Chemetrix makes the rest straightforward too.

Ready to stop second-guessing your FTIR results?

📩 Contact the Chemetrix team to book a workflow audit, arrange a Cary 630 demonstration or discuss building your Golden Reference Library: chemetrix.co.za

The Method Validation Wall: Why Elemental Impurity Compliance Stalls and How to Break Through It

There is a particular kind of silence in a pharmaceutical audit that every QA manager knows. It is not the silence of a clean room or an empty corridor. It is the silence after an inspector closes a data file, looks up and says nothing because everything is in order. That silence is the goal. And in elemental impurity testing, it is harder to achieve than most labs expect.

ICH Q3D and USP chapters 232 and 233 set mandatory limits for elemental impurities in pharmaceutical products. Compliance is not discretionary. It is not a best practice recommendation. It is a regulatory requirement that applies to every oral and parenteral drug product on the market. The question is not whether your lab will comply, but whether your workflow can prove it, consistently, at trace levels, across every batch, under inspection.

This article explains where most labs stall, why the problem is almost always a process issue rather than a hardware issue, and how a validated ICP-MS workflow built on the right instrumentation and partnership gives you the audit confidence you need.

What is the real cost of getting elemental impurity testing wrong?

Elemental impurities are unwanted inorganic elements that enter pharmaceutical products through raw materials, metal catalysts used in synthesis, manufacturing equipment or packaging. They include Class 1 elements such as arsenic, cadmium, lead and mercury, which carry the highest toxicological risk, through to Class 2 and Class 3 elements with route-specific exposure limits. None of them belong in a finished drug product above their permissible daily exposure levels, and none of them are detectable by visual inspection, smell or conventional wet chemistry.

This is what makes a compliance failure in this category so damaging. By the time a contamination event is discovered, product has often already been distributed. The financial cost of a recall is significant. The cost to patient trust is permanent. And because elemental impurities at toxic concentrations produce no visible sign of product degradation, the only defence is a validated analytical method that catches them before the product leaves the facility.

The pressure is continuous. Batch testing is not a one-time validation exercise. It is a routine, recurring obligation that runs for the entire commercial life of the product. Every batch. Every route of administration. Every manufacturing site change. The workflow that handles this cannot be fragile, analyst-dependent or difficult to defend under scrutiny.

What do ICH Q3D and USP 232/233 actually require?

ICH Q3D is the international harmonised guideline for elemental impurities in pharmaceutical products. It is adopted by the US Food and Drug Administration, the European Medicines Agency, Japan’s Pharmaceuticals and Medical Devices Agency and other global regulatory bodies. It establishes permissible daily exposure limits for a defined set of elemental impurities across oral and parenteral administration routes.

USP chapter 232 sets the acceptance criteria, defining the specific concentration limits for each element by route of administration. USP chapter 233 defines the analytical procedures required to demonstrate compliance, including the method validation parameters of specificity, linearity, accuracy, precision and detection limits.

The analytical techniques specified under USP 233 for elemental impurity analysis are ICP-MS and ICP-OES. These are the techniques that provide the ideal capabilities for determining inorganic contaminants to ICH Q3D and USP 233 requirements. Between the two, ICP-MS is the instrument of choice for most pharmaceutical laboratories, offering superior sensitivity at trace and ultra-trace concentration levels across the full range of regulated elements. ICP-OES is well suited to elements present at higher concentrations and to laboratories where the breadth of the ICP-MS dynamic range is not required for every element in scope.

Together, ICH Q3D, USP 232 and USP 233 define not just what must be measured, but how the measurement must be proven to work and on which platform. The regulatory framework is specific. The instrumentation it points to is equally specific.

Where does the ICP-MS workflow actually break down?

The Chemetrix team consistently identifies method validation as the point where pharmaceutical labs stall. Not instrument performance.
Not detection capability. Method validation.

The leap from early-stage R&D profiling, where the goal is elemental detection and characterisation, to validated routine QC, where the goal is defensible batch release data, is significant. In R&D, an analyst runs a method, gets a result and moves on. In QC, that same method must be formally validated, transferred to a different instrument or operator, proven robust across variations in sample matrix and demonstrated to remain fit for purpose over time.

This is where the human and process variables multiply. Instrument-to-instrument method transfer introduces drift. Analyst-to-analyst variability in sample preparation introduces inconsistency. Calibration standard preparation from single-element solutions introduces calculation errors and traceability gaps. Any one of these variables can generate an audit finding, not because the underlying science was wrong, but because the documentation did not adequately capture what was done and why.

The calibration standard problem deserves particular attention. Preparing ICP-MS calibration solutions for a multi-element elemental impurity method from individual single-element stock solutions is time-consuming, error-prone and difficult to trace. A single pipetting error, an incorrect dilution factor or a matrix mismatch between the standard and the sample can compromise the entire run. In a routine QC environment running batch after batch, these risks compound over time.

Chemetrix Insight: “In ICP-MS-based elemental impurity testing, the strongest flagship is not the data. It is the defensibility of that data.”

How do you build a validated ICP-MS elemental impurity workflow that holds up under inspection?

The answer is to remove as many human variables as possible before the method reaches routine QC. For ICP-MS elemental impurity workflows, this starts with the reference materials.

Use pre-formulated, certified reference material kits designed specifically for USP 232/233

Agilent’s ICH Q3D/USP 233 Elemental Impurities Portfolio does exactly this. The portfolio includes certified reference material kits for both oral and parenteral routes, with elements sorted by ICH and USP class, chemical compatibility and relative mandated concentrations.

This design eliminates the need for analysts to prepare their own calibration standards from single-element solutions, removing the most significant source of human error in the ICP-MS calibration workflow. Instead of calculating and preparing multi-element mixes from scratch, analysts work from pre-formulated, ready-to-use solutions that are already matched to the permissible daily exposure levels required by the method.

The kits are manufactured in an ISO 17034-accredited facility and certified in an ISO/IEC 17025 testing laboratory. Each kit is supplied with a Certificate of Analysis confirming actual concentrations, measurement uncertainty and NIST traceability. A dedicated Pharma Internal Standard Solution is included, optimised specifically for ICP-MS and ICP-OES results with common pharmaceutical sample types, which is critical for accurate internal standardisation across the wide mass range covered by a full USP 232/233 elemental panel.

Agilent has also updated these kits to reflect the most recent USP 232 guideline changes, which increased the permissible limits for gold and silver. Using current, regulatory-aligned certified reference materials is a fundamental audit requirement and one that is easily overlooked when laboratories are managing their own standard preparation programmes.

Build on preset ICP-MS methods designed for USP 232/233 compliance

Agilent ICP-MS and ICP-OES platforms include preset methods built specifically for ICH Q3D and USP 232/233 compliance. This reduces the configuration burden during method transfer from R&D to QC and provides a validated starting point that is consistent across instruments, reducing the risk of method drift between sites
or between analysts.

What makes the ICP-MS the right platform
for pharmaceutical elemental impurity compliance?

The ICP-MS is the primary instrument for pharmaceutical elemental impurity testing because the regulatory requirements demand it. USP 233 specifies trace-level multi-element analysis across a wide range of elemental classes with strict accuracy and precision requirements.
ICP-MS is uniquely suited to this task, offering the sensitivity, selectivity and multi-element capability that the method demands.

For pharmaceutical applications specifically, the combination of the Agilent ICP-MS platform with the ICH Q3D/USP 233 certified reference material kits creates a complete, traceable, regulation-aligned solution. The oral kit covers the full panel of elements required for oral drug product release. The parenteral kit addresses the tighter permissible daily exposure limits applicable to injectable and infusion products, where the regulatory scrutiny is highest.

The Agilent ICP-OES platform extends this capability to elements present at higher concentration ranges, and provides a complementary option for laboratories where the full sensitivity range of ICP-MS is not required for every element in scope. For many pharmaceutical laboratories, ICP-MS and ICP-OES are used together to cover the complete elemental panel efficiently.

Agilent’s OpenLAB Software Suite supports data management and analysis across the ICP-MS and ICP-OES platforms, maintaining the data integrity and audit trail controls required in a regulated pharmaceutical environment. Analytical Instrument Qualification and Functional Verification services are available from Agilent to support regulatory submissions and inspection readiness, ensuring that the instrument performing the analysis is as well-documented as the method itself.

📌 Ask Chemetrix about configuring a complete ICP-MS elemental impurity compliance workflow, including reference materials, method setup and instrument qualification.

Audit-ready is not a feature, it is a service

Supplying an Agilent ICP-MS system is the beginning of the story, not the end. The instrument is capable. Whether the workflow built around it is defensible under inspection is a different question entirely, and it is the question that Chemetrix answers.

Too many labs reach the method validation wall and stall there. They have the instrument. They have the regulatory guidance. But the gap between a working ICP-MS method and a validated, documented, transferable method that survives an audit is wider than most labs anticipate when they start the project.

Chemetrix closes that gap through three specific services:

  • Method Development and Transfer: Chemetrix does the heavy lifting of trace-level ICP-MS method development, building validated elemental impurity procedures that are designed from the start to transfer cleanly from R&D to routine QC without drift. This includes worst-case element selection, matrix-matched calibration design and the full validation parameter set required by USP 233.
  • Routine Batch Reliability: Long-term instrument stability for recurring batch testing does not happen automatically. Chemetrix provides the service framework that keeps ICP-MS instruments qualified, certified reference materials current and data trails complete, so that the programme running today is still audit-ready in three years.
  • Audit-Ready Documentation: From instrument qualification records through to method validation reports and standard operating procedures, Chemetrix helps build the documentation package that turns a technically sound ICP-MS workflow into a regulatorily defensible one.

Compliance is mandatory. The data alone is not enough.
It is the documented, traceable, reproducible system behind the data that gives regulators confidence and gives patients the protection they are owed.

Conclusion

Elemental impurity compliance under ICH Q3D and USP 232/233 is one of the most technically demanding and most consequential analytical obligations in pharmaceutical manufacturing. The stakes are patient safety. The standard is mandatory. And the challenge is not the sensitivity of the ICP-MS. It is the defensibility of the workflow built around it.

The three things to take away from this article:

  • ICP-MS is the primary analytical platform specified for USP 232/233 compliance. Building your elemental impurity workflow around a purpose-designed, regulation-aligned ICP-MS configuration is the most direct path to audit readiness.
  • Pre-formulated certified reference material kits remove the single biggest human variable in the ICP-MS calibration workflow. Agilent’s ICH Q3D/USP 233 portfolio is manufactured to ISO 17034 and certified to ISO/IEC 17025, with NIST-traceable Certificates of Analysis for every kit.
  • The silence of a successful audit is earned, not assumed. It comes from a validated ICP-MS system, traceable reference materials, consistent sample preparation and documentation that tells a complete and accurate story.

The Agilent ICP-MS platform and certified reference material portfolio provide the instrumentation and standards. Chemetrix provides the validated workflow, the ongoing support and the audit-ready confidence that makes elemental impurity compliance continuous rather than periodic.

Ready to move from compliance pressure to compliance confidence?

📩 Contact the Chemetrix team to discuss ICP-MS configuration, reference material selection or audit preparation for your elemental impurity programme: chemetrix.co.za

How to Get Consistent, Defensible Cleaning Validation Results with the Veolia Sievers M9

The batch is ready. The vessel looks clean. But the documentation is not done, the QC queue is backed up and the equipment has been sitting idle waiting on analytical results.

This is the real cost of a slow or uncertain cleaning validation programme. Not the cost of the instrument. Not the complexity of the method. The cost is measured in hours of lost production, delayed releases and the quiet anxiety of knowing that if an inspector walked in right now, your data trail would not tell a clear and convincing story.

Total organic carbon (TOC) analysis exists precisely to eliminate that anxiety. When implemented correctly, it is one of the fastest, most regulator-friendly, and most operationally practical cleaning verification methods available. This article explains why so many labs are not using it that way and what it takes to change that.

What does a failed clean actually cost?

Most cleaning validation conversations start with the method. They should start with the consequence. A single failed clean in a pharmaceutical or food manufacturing facility does not just mean re-cleaning the vessel. It means halting production, quarantining potentially affected batches, initiating a deviation investigation, documenting the root cause, re-validating the cleaning cycle and demonstrating to QA that it will not happen again. In a worst-case scenario, that is days of downtime on a critical piece of manufacturing equipment.

The Chemetrix team has seen this play out in facilities relying on product-specific methods like HPLC for cleaning verification. When an unknown degradant or cleaning agent residue slips through undetected, the specific method offers no warning. TOC does. Because it measures the total organic carbon in a rinse or swab sample, it catches APIs, degradants, excipients and cleaning agents in a single analysis. There is no invisible contamination with a properly implemented TOC method.

The three most common operational pain points the Chemetrix team identifies in cleaning validation programmes are:

  • Poor worst-case selection. Labs test the wrong compound or the wrong surface area, which means their validation does not reflect real-world cleaning challenges.
  • Weak limit translation. There is a well-defined ppm requirement on paper, but nobody has converted it into an actionable TOC concentration limit for the instrument.
  • Inconsistent sampling. Swab technique varies between analysts, water baseline is not controlled and grab samples represent a single timepoint rather than a continuous view of the cleaning cycle.

These are workflow problems. Not instrument problems.

Why is TOC considered the gold standard for cleaning validation?

TOC analysis works by oxidising all organic residues in a sample and measuring the carbon dioxide produced. The result is a single, quantitative carbon concentration value that tells you, objectively, how much organic material remains on the equipment surface or in the final rinse.

This matters enormously in a regulated environment because it removes operator subjectivity from the result. There is no peak integration to argue about, no ghost peaks to investigate and no ambiguity about whether a signal is real or an artefact. The FDA has issued numerous warning letters specifically for HPLC data integrity failures, including failure to integrate peaks and inadequate investigation of unknown peaks. These problems are structurally unavoidable in product-specific methods because cleaning processes generate degradants and unexpected compounds that the specific method was never designed to detect.

TOC does not have this problem. It detects everything organic. That is not a liability. That is a feature. The regulatory acceptance of TOC for cleaning validation is well established. The US Pharmacopoeia, the US Food and Drug Administration and the European Medicines Agency all recognise TOC as an appropriate and compliant method for demonstrating equipment cleanliness. The FDA’s 2011 process validation guidance is particularly significant: the traditional practice of measuring a single API with a specific method is no longer considered compliant with FDA best practice, because it does not provide the process understanding the life cycle approach requires. TOC, as a non-specific method, measures both product-related and process-related residues as a function of carbon content, making it compliant with that guidance and giving a comprehensive view of cleanliness at every phase of the validation life cycle.

When sensitivity becomes a concern, it is worth reframing the question:

A TOC analyser is not too sensitive. It is appropriately sensitive. Sensitivity is exactly what guarantees that equipment is genuinely clean, not just clea

n enough to pass a method that was not looking for everything.

Is TOC actually cheaper than HPLC for cleaning validation?

The short answer is yes – in most cases, TOC is more cost-effective than HPLC, often delivering noticeable savings within the first year of implementation.

Here is what a realistic comparison looks like across the two approaches:

HPLC for cleaning validation requires a separate, validated method for each product. Method development is time-consuming and assumes that all potential interferents are fully understood. It cannot detect degradants or cleaning agent residues that fall outside the target compound. Laboratory workflow typically means grab samples are transported to the QC lab, queued for analysis and results returned hours later. Equipment sits idle during this time.

TOC for cleaning validation requires a single method that covers APIs, excipients, degradants and cleaning agents simultaneously. The Sievers M9 delivers results in two minutes in standard mode, or four seconds with the optional Turbo mode. The M9 Portable model can be taken directly to the manufacturing floor, samples can be analysed almost immediately after collection and equipment can be released faster.

The economic gains compound over time. Fewer out-of-specification investigations due to environmental or transcription errors, faster analyst throughput, reduced re-testing and the elimination of mobile phase preparation all contribute to a meaningfully lower total cost of running a cleaning validation programme.

Chemetrix Insight: “TOC almost always reduces total validation costs within the first year by accelerating batch release and reducing the frequency of re-testing. The instrument cost is recovered faster than most labs expect.”

How do you troubleshoot a TOC cleaning validation workflow that is not performing?

When TOC results are inconsistent or a cleaning validation programme is not delivering the confidence it should, the problem is almost never the analyser. Here is the hierarchy of where to look first.

Step 1: Check the water baseline. The carbon contribution of the rinse water itself must be established and controlled. If the water baseline is elevated or variable, every subsequent result will be unreliable. Low-TOC water and appropriate Sievers certified vials are the foundation of reproducible results.

Step 2: Review the swab technique. Analyst-to-analyst variability in swabbing is one of the most common sources of inconsistency in cleaning validation data. In published validation data using the Sievers M9, two different analysts achieved recovery values of 100% to 105.8% with RSD values below 2.1% for the same CIP-100 cleaning agent at multiple concentration levels, demonstrating that a well-standardised method is highly reproducible across operators. If your res

ults do not look like this, the method has not been standardised, not the instrument.

Step 3: Confirm the worst-case compound is correctly identified. Many facilities test the easiest-to-detect compound rather than the hardest-to-clean one. Worst-case selection should be based on solubility, toxicity and difficulty of removal, not analytical convenience.

Step 4: Verify the limit is correctly translated. A product limit expressed in ppm of compound is not directly equivalent to a TOC limit. The conversion requires multiplying by the percentage carbon in the chemical formula of the compound. For example, if a specific API limit is 10 ppm and the percentage carbon is 50%, the TOC limit is 5 ppm. This step is frequently skipped or done incorrectly.

Step 5: Consider the deployment. If equipment turnaround is the primary constraint, laboratory-based grab sample analysis may simply not be fast enough. At-line analysis with the M9 Portable or online analysis with the M9 On-Line can eliminate the QC queue entirely and enable real-time equipment release.

Practical resources:

  • Veolia Application Note: Validating the TOC Method for Cleaning Validation Applications in the Pharmaceutical Industry
  • Veolia Fact Sheet: Top 5 Secrets to a Successful Cleaning Validation Program
  • Veolia eBook: Total Organic Carbon for Cleaning Validation Programs
📌 Contact Chemetrix to request a workflow review of your current cleaning validation programme.

What makes the Veolia Sievers M9 the right instrument for pharmaceutical cleaning validation?

The Sievers M9 was not designed for a research scientist with unlimited time. It was designed for the QC technician who needs to verify that a vessel is clean, release the equipment and get back to supporting production. That distinction matters.

The Sievers Membrane Conductometric Detection method is what sets the M9 apart technically. Unlike instruments that use non-dispersive infrared (NDIR) detection, the Sievers gas-permeable membrane selectively passes only the CO₂ produced from the oxidation of organics. Acids, bases and halogenated compounds, which are frequently present in pharmaceutical cleaning processes, are prevented from interfering with the measurement. This delivers selectivity and precision in exactly the sample matrices where cleaning validation is performed.

The M9 comes in three configurations to match any deployment need:

  • M9 Laboratory: For QC labs running high volumes of rinse and swab samples, with optional Autosampler for 24-plus hours of unattended analysis
  • M9 On-Line: Attached directly to a CIP skid for continuous real-time monitoring and automated equipment release without any manual sampling
  • M9 Portable: Lightweight and IP-21 rated for at-line use on the manufacturing floor, supporting both rinse and swab samples with optional Turbo mode

Across all three configurations, the M9 delivers a measurement range of 0.03 ppb to 50 ppm with precision below 1% RSD and accuracy of plus or minus 2% or plus or minus 0.5 ppb, whichever is greater. Calibration is typically stable for 12 months. Maintenance requires just a few hours per year. The instrument comes pre-calibrated from the factory and can be prepared for analysis in under one hour.

For regulated environments, the optional DataGuard software provides full 21 CFR Part 11 and Annex 11 compliance, with a secured audit trail, user-level access controls and data that cannot be modified or deleted. The M9 also simultaneously reports TOC, inorganic carbon and conductivity from a single sample, giving three discrete data points that can be used together to identify root cause, optimise cleaning cycles and support OOS investigations.

Practical resources:

  • Veolia Application Note: Validating the TOC Method for Cleaning Validation Applications in the Pharmaceutical Industry
  • Veolia Fact Sheet: Top 5 Secrets to a Successful Cleaning Validation Program
  • Veolia eBook: Total Organic Carbon for Cleaning Validation Programs
📌 Contact Chemetrix to request a workflow review of your current cleaning validation programme.

Stop blaming the instrument and fix the workflow

The most common story Chemetrix hears is some version of this: “We tried TOC. It did not work for us.” After closer investigation, the story is almost always the same. The water baseline was not controlled. The worst-case compound had not been properly identified. The limit had not been correctly translated from ppm of compound to a TOC concentration. The sampling was inconsistent between analysts.

The instrument was fine. The workflow was not.

Chemetrix does not just supply a Sievers M9 and move on. The partnership Chemetrix offers is built around making sure the workflow is right before the instrument is even switched on, and that the team running it has the knowledge to trust the results it produces.

This means three specific things in practice:

  • Worst-Case Selection Support: Helping your team identify which compound, which equipment surface and which cleaning cycle represents the genuine worst case for your process, so your validation is defensible under inspection.
  • Limit Translation: Converting your existing acceptance criteria into actionable TOC concentration limits, accounting for the percentage carbon in the chemical formula and the sampling method used.
  • Sampling Standardisation: Establishing consistent swab technique, water baseline controls and vial selection across your team so that analyst-to-analyst variability is eliminated as a source of OOS investigations.

When results are consistent, compliance follows. That is not a slogan. It is the operating principle of a cleaning validation programme that works.

Conclusion

Cleaning validation does not have to be the bottleneck it has become in many facilities. The science is straightforward. The regulatory acceptance is well established. The instrument is reliable, automated and designed for QC technicians rather than research scientists.

The three things to take away from this article:

  • TOC catches what specific methods miss. APIs, degradants, excipients and cleaning agents are all detected in a single analysis, making it inherently more comprehensive than HPLC for cleaning verification.
  • Most TOC problems are sampling and workflow problems. Controlling the water baseline, standardising swab technique and correctly translating limits will resolve the vast majority of analytical inconsistencies.
  • The Sievers M9 is built for production environments. With two-minute analysis time, optional Turbo mode at four seconds, three simultaneous data outputs and 21 CFR Part 11 compliance, it is designed to release equipment and get out of the way.

The Sievers M9 delivers consistent, defensible proof that cleaning works. Chemetrix makes sure your workflow does too.

Ready to stop guessing and start releasing?

📩 Contact the Chemetrix team to book a cleaning validation workflow audit or arrange a Sievers M9 demonstration: chemetrix.co.za

The Intelligent Lab: How AI and Advanced Metabolomics are Redefining Scientific Discovery

The pace of scientific discovery is no longer governed solely by the physical limits of manual experimentation. We are currently witnessing a shift that is as transformative as the invention of the microscope itself. Artificial Intelligence (AI) and advanced metabolomics are reshaping how science is conducted, moving research from a “trial-and-error” model to a predictive, data-driven discipline. By combining high-resolution analytical hardware with machine learning, laboratories can now solve complex biological challenges – such as developing animal-free culture media – with unprecedented speed.

The complexity of the modern workflow

In the fast-evolving landscape of biopharmaceuticals and cell biology, the reliance on traditional methods often leads to significant hurdles. For decades, the industry has relied on fetal bovine serum (FBS) to supplement cell culture media, despite its high costs, ethical concerns, and inherent inconsistency.

Many lab teams find themselves buried under mountains of raw data from complex matrices, struggling to identify which specific molecular components actually drive performance.

When dealing with undefined raw ingredients, such as plant and microbial extracts, understanding chemical composition is critical to ensuring batch-to-batch reproducibility and process continuity when scaling.

From raw peaks to actionable insights

The challenge in modern labs isn’t a lack of data; it is the complexity of interpreting high-dimensional datasets. Manual analysis of thousands of formulations is no longer feasible. As regulatory requirements for biologics become more stringent, the demand for defined, reproducible, and regulatory-compliant media has grown.

Advanced metabolomics provides the molecular profiling required to qualify raw materials, while AI handles the broad combinatorial screening. This synergy allows researchers to tailor media composition to specific cell lines, improving yield and efficiency across the drug development lifecycle.

Optimising media with LC/Q-TOF

To solve the media development challenge, Chemetrix supports the implementation of untargeted metabolomic workflows. By utilising the Agilent 6545 LC/Q-TOF, labs can perform detailed molecular characterisation of both raw materials and finished formulations.

How Chemetrix assists:

Our specialists help your team establish metabolomic workflows that provide detailed molecular information for R&D. We assist in identifying “critical component targets” – biomarkers of performance – that become your QC benchmarks. By linking these molecular features to cellular outcomes, we help you replace inconsistent serums with precise, scalable,
animal-free alternatives.

Agilent 6545 LC/Q-TOF

Predictive productivity

Efficiency in the modern lab is increasingly driven by smart automation. The Agilent Infinity III LC Series is designed to address the operational risks that lead to downtime and lost samples through integrated AI-powered solutions.

How Chemetrix assists:

Chemetrix provides the technical expertise to integrate these platforms into your existing regulatory-ready environment. The Infinity III offers predictive analytics and real-time alerts to pre-empt operational failures. We assist in configuring these advanced informatics platforms so that your lab can handle complex workflows with greater precision. This shift to an automated, AI-enabled system allows your staff to focus on high-value data interpretation rather than routine manual monitoring.

Compressing development from years to months

The shift toward AI-guided development marks a new paradigm in biological optimisation. By continuously training algorithms with high-quality experimental data, each project makes the platform more intelligent. This iterative process has the power to compress development cycles that once took years into just a few months. When molecular characterisation is linked directly to cellular performance, the result is a more resilient supply chain and a faster time-to-market for novel therapies.

Optimising the path to discovery

The integration of AI and separation science is no longer a luxury; it is the foundation for the next generation of bioprocess innovation. At Chemetrix, we provide the local application expertise and technical support required to navigate these digital transformations.

Your action plan

Identify a workflow in your lab that currently relies on undefined ingredients or manual screening. Contact a Chemetrix specialist today for a workflow audit. We will help you leverage advanced metabolomics and AI-powered instrumentation to ensure your processes are reproducible, compliant, and ready for the future of biomanufacturing.

Beyond the Bench: Why Partnership is the Critical Component in Pharmaceutical Analysis

In the pharmaceutical industry, the most valuable asset isn’t the active ingredient or the patented molecule – it is the integrity of the data that proves it works. In a sector governed by uncompromising regulatory standards, a laboratory’s reputation is built on its ability to produce consistent, compliant, and accurate results. However, as drug formulations grow more complex and detection limits move lower, many laboratories find that having the right equipment is only half the battle. The real challenge lies in the support system that keeps that equipment performing within the narrowest of margins.

At Chemetrix, we have been an authorised Agilent distributor in Southern and East Africa for decades. While our heritage is diverse, our commitment to the pharmaceutical sector is foundational. We don’t just supply instruments; we provide the technical scaffolding that allows pharmaceutical analysts to move from a raw sample to a validated report with total confidence.

Why great hardware isn’t enough

One of the most persistent challenges in the pharmaceutical workflow is the transition from a concept to a robust, validated method. It is a common misconception that high-end instrumentation automatically guarantees ease of use. In reality, pharmaceutical analysts often struggle with the “blank space” between unboxing an instrument and running their first compliant sample.

Whether you are identifying trace impurities, performing stability testing, or conducting complex bioanalysis, the method development phase is often where projects stall. A method that works in a controlled environment can fail in a high-throughput production setting if it hasn’t been stress-tested for robustness. This leads to a reactive cycle of troubleshooting and re-validation, which drains resources and delays time-to-market.

Navigating a shifting regulatory landscape

Data integrity is the non-negotiable cornerstone of the pharmaceutical industry. Global research shows that 90% of pharmaceutical professionals agree that reliable instruments are the single most important factor for a successful workflow. This is because, in this sector, a failure in reliability is a failure in compliance.

The pressure to process more samples while maintaining absolute adherence to 21 CFR Part 11 and EudraLex Annex 11 is immense. Without a partner who understands the nuances of IQ/OQ (Installation and Operational Qualification) and ongoing maintenance, labs risk falling into the “efficiency gap.” This is where sophisticated instruments sit underutilised because the method is too temperamental or the staff lack the specific training required to navigate the software’s compliance features.

Mastery of complex matrices with Agilent LC/MS

For laboratories tackling the most demanding pharmaceutical applications – such as nitrosamine analysis or impurity profiling– Agilent’s LC/MS solutions are globally recognised as the definitive standard. These systems provide the sensitivity and specificity required to detect analytes at levels that were previously unimaginable.

However, the “Chemetrix Edge” lies in how we support this technology. We recognise that method development for LC/MS is a specialised skill. Our support department acts as an extension of your own team, providing on-site assistance to help you develop, optimise, and troubleshoot your pharmaceutical methods. By leveraging our local application expertise, you can reduce the time spent in method development and ensure that your LC/MS system is performing at its peak from day one.

Driving throughput with the Agilent 1290 Infinity III LC

The workhorse of any modern pharmaceutical lab is the Liquid Chromatograph, and the Agilent 1290 Infinity III LC is engineered specifically for high-throughput environments. It is designed to handle the everyday pressures of pharmaceutical analysis with ultra-low carryover and exceptional pressure stability.

Chemetrix supports this hardware through a comprehensive service programme that goes beyond simple repairs. We offer tailored preventive maintenance and rapid-response technical support to ensure your 1290 Infinity III stays in a qualified state. By integrating our service expertise with this robust hardware, we help labs eliminate the “time traps” of manual intervention. Our goal is to ensure your staff spend less time worrying about baseline
drift and more time focusing on high-value data interpretation.

Agilent 1290 Infinity III LC

The reward of proactive support

The transition from a reactive laboratory to a proactive one is transformative. When you partner with a specialist who understands pharmaceutical applications, the results are measured in more than just uptime. You gain the peace of mind that comes from knowing your methods are robust, your instruments are qualified, and your data is defensible.

Our most successful pharmaceutical partners are those who have moved away from viewing instrumentation as a commodity and have embraced it as a collaborative workflow. This partnership leads to faster validation cycles, fewer “Out of Specification” (OOS) investigations, and a laboratory team that is empowered by their technology rather than frustrated by it.

 

Take the next step in laboratory excellence

The road to an optimised pharmaceutical workflow doesn’t have to be a solitary one. Whether you are looking to expand your LC/MS capabilities or need to refine the efficiency of your current chromatography setup, the expertise you need is available locally.

Your Action Plan:

Identify your most temperamental method – the one that requires the most manual intervention or frequent re-runs. Contact a Chemetrix specialist today for a workflow audit. Let’s work together to resolve your method development challenges and ensure your lab is equipped for the future of pharmaceutical discovery.

From Manual to Mindful: Harnessing Automation and Intelligence in the Modern Laboratory

In the fast-paced world of laboratory science, the pressure to deliver results is relentless. Imagine this: it’s 4:00 PM on a Friday, and your high-priority sample run just failed due to a sudden instrument blockage. Or perhaps you are staring at a mounting backlog of samples, but your bench space is at its limit and your budget for new hires is non-existent.

If this sounds familiar, you aren’t alone. Modern laboratories are no longer just places of discovery; they are high-pressure environments where efficiency, accuracy, and cost-control must live in perfect harmony. But how do you scale your output without scaling your stress levels?

 

The growing pains of the modern lab

The challenges facing today’s lab managers are multifaceted. According to global research by Agilent, a staggering 45% of lab managers face significant pressure to process more samples, yet they are expected to do so without increasing operational costs.

Beyond volume, there is the hurdle of unplanned downtime. Around 75% of lab managers cite instrument maintenance and downtime as their biggest headache. In the pharmaceutical sector, this figure rises even higher, where 90% of professionals agree that reliable instruments are the single most important factor for a successful workflow. Add to this the physical constraints of small laboratory premises and the constant evolution of regulatory standards, and it is easy to see why many feel they are running to stand still.

 

 

Navigating the efficiency trap

When we talk about “lab efficiency,” we often think of speed. However, true efficiency is about data integrity and resource management. Many laboratories still rely on manual processes that are prone to human error, leading to costly re-tests.

Data shows that in many traditional setups, some lab instruments are only being utilised 35% of the time, while the rest of the day is lost to manual sample preparation, cleaning, or waiting for repairs.

 

This “efficiency gap” doesn’t just slow down research; it eats into the bottom line and delays life-changing products from reaching the market.

 

Automating the mundane with Chemetrix

One of the most effective ways to reclaim your time is through Lab Automation. Chemetrix positions itself as more than a supplier; we are a partner in your workflow. By identifying “time traps” in your daily routine – such as repetitive liquid handling or manual SPE (Solid Phase Extraction) – we can help you transition to a smarter way of working.

A standout solution in this space is the Agilent 1260 Infinity III LC System. This instrument is a workhorse designed for the “everyday” challenges of a busy lab. It allows you to mix and match modules with existing setups, meaning you don’t have to overhaul your entire lab to see an immediate boost in throughput. Chemetrix assists by providing the technical expertise to integrate these systems seamlessly, ensuring your staff are trained to focus on high-value data interpretation rather than the repetitive motion of pipetting.

 

Explore the modules:
Agilent 1260 Infinity III Diode Array Detector – Wide Range

Agilent 1260 Infinity II Multi-Angle Light Scattering Detector

 

Smarter analysis with the 8890 gas chromatograph

Maintenance shouldn’t be a game of “wait and see.” To combat the 75% of downtime caused by maintenance issues, Chemetrix recommends moving toward Instrument Intelligence.

 

The Agilent 8890 GC System is the gold standard for labs looking to eliminate guesswork. This instrument features built-in intelligence that monitors its own health, providing digital alerts for regular maintenance before a failure occurs. It even offers step-by-step instructions on-screen for common maintenance procedures.

 

When you partner with Chemetrix, you gain access to our “Support When You Need It” guarantee. Our experts don’t just deliver a box; we help you configure the 8890 to your specific applications – whether that’s environmental testing or complex chemical analysis – ensuring maximum uptime and a much higher return on investment.

 

Agilent 8890 GC System

 

From pressure to productivity: The power of partnership

The ultimate goal of any laboratory is to produce results that make a difference. When you move from a reactive “fix-it” mindset to a proactive, automated workflow, the results are transformative.

Imagine a lab where instruments “hum” along without intervention, where data integrity is guaranteed by digitisation, and where your team has the breathing room to innovate. This isn’t a futuristic dream; it is the reality for laboratories that have embraced smarter technology. By reducing manual intervention, you not only increase your sample capacity but also improve the morale of your team, allowing them to do the science they were actually trained for.

 

 

Take the first step towards a smarter lab

You don’t have to solve every challenge at once. Improving lab efficiency is a journey, and it starts with a single conversation. Whether you’re struggling with limited bench space, rising costs, or frustrating downtime, the team at Chemetrix is ready to listen.

Your next move: Why not audit your current workflow? Identify your biggest “time trap” and contact a Chemetrix expert today for a tailored consultation. Let’s work together to turn your laboratory challenges into your greatest competitive advantage.

 

Visit our website to explore our full range of analytical solutions or join one of our upcoming webinars to learn how to free your workflow from common time traps.